Both in Pharmaceuticals
Crescent Biopharma vs Monopar Therapeutics
Over the past year CBIO returned +20.6% and MNPR returned −3.2%; their daily moves had a correlation of 0.16.
CBIO +20.6% MNPR −3.2%Growth of $1, one year, split-adjusted
| Metric | CBIO | MNPR |
|---|---|---|
| Price | $14.34 | $79.08 |
| Market cap | $532.7M | $530.8M |
| Today | −1.71% | −0.74% |
| 1 month | −20.0% | −32.7% |
| 6 months | −25.8% | +42.8% |
| Year to date | +20.9% | +21.1% |
| 1 year | +20.6% | −3.2% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | 44.8× | — |
| Net cash | $171.6M | $134.3M |
| Dividend yield | — | — |
| Volatility (60d) | 77.1% | 58.0% |
| Short % of float | 16.3% | 17.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).